David Spetzler

North Texas’ Caris Life Sciences Gets FDA Approval for its ‘MI Cancer Seek’ Companion Diagnostic Test

by | Nov 6, 2024
Caris said MI Cancer Seek will be used as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
MORE
Dr. David Spetzler
Caris Life Sciences Partners with Moderna To Advance mRNA-Based Cancer Drugs
by | Oct 24, 2023
Irving-based Caris said that via this multiyear agreement, Moderna will leverage Caris’ extensive library of de-identified, multimodal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses—along with claims data to improve development strategies for Moderna’s oncology pipeline.
MORE
Caris Life Sciences and ConcertAI Announce New Clinico-Genomic Research Platform
by | Jun 1, 2023
Expanding a collaboration they announced in January, the two companies aim to drive "the future of cancer care" with the new platform, enabling novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
MORE